Catalyst Wire Dossier Catalyst Wire Dossier

GRF312 5%

· Instituto Grifols, S.A.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GRF312 5%, covering 2026-02-13 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). [Phase 2]

See pricing